Can you provide clinical profiles where there is a strong rationale to move from a regimen of metformin and SGLT2 inhibitor, to a fixed ratio combination of a basal insulin plus GLP-1 RA?

Can you provide clinical profiles where there is a strong rationale to move from a regimen of metformin and SGLT2 inhibitor, to a fixed ratio combination of a basal insulin plus GLP-1 RA?

Can you provide clinical profiles where there is a strong rationale to move from a regimen consisting of metformin and SGLT2 inhibitor, to a fixed ratio combination of a basal insulin plus GLP-1 RA?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

James Gavin III, MD, PhD

James Gavin III, MD, PhD

Clinical Professor of Medicine
Emory University School of Medicine
Atlanta, Georgia
Clinical Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana